The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Hiromichi Shirasu
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Ono Yakuhin; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Takeda (Inst)
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Manabu Shiozawa
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Takashi Ohta
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Taiho Pharmaceutical; Takeda; Teijin Pharma
 
Naoki Takahashi
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical; Taiho Pharmaceutical
 
Tadamichi Denda
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Daiichi-Sankyo; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQVIA (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Dainippon Pharma (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst)
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yukiko Abe
No Relationships to Disclose
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Bio
Research Funding - Amgen Astellas BioPharma (Inst); AstraZeneca (Inst)
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)